Gastroenterology Medicine Manufacturer

Aprazer Healthcare Redefines Gastroenterology care by developing premium-quality therapeutics, including both over-the-counter and prescription medicines.

Aprazer Healthcare Develops Cost-effective Treatments

Recognizing the demand for cost-effective treatments in IBD and MASH.

We develop scientifically backed solutions for organic GI disorders, addressing the critical patient needs – bridging the gap of unavailability, inadequate therapeutic efficacy, and affordability.

Reliable Effective Care

With our strong foundation and expertise in gastroenterology, we prioritize reliability, creating solutions that are both safe and effective.

Expanding the Frontiers of Gastroenterology & Hepatology

From developing the first-line treatment for Primary Biliary Cholangitis (PBC), Udikast (UDCA) 300 mg, and the Ocabest 5 mg, (OCA) with stronger ant fibrotic effects, we develop the widest range of gastroenterology and hepatology treatments including:

• 1. Proton pump inhibitors
• 2. Anti-inflammatory Agents
• 3. Gastrointestinal-selective antibiotics
• 4. Hepatoprotective Agents

Leaders in Gastroenterology Medicine Manufacturers, Suppliers, and Exporters

• • With a high degree of supply assurance
• • Manufacture capacity of 100 multi-tones
• • Suppliers to more than 20 countries

We are well-positioned to meet the global demand for gastroenterology and hepatology therapeutics.

Shaping the Future in Digestive Care

We focus on advancing breakthrough therapeutics to reduce the global burden of gastrointestinal disorders, Such as IBD, NAFLD, NASH, Gastritis, and ulcerative colitis.

Our premium-selling medications—EPRAKAST DSR, targeting acid-related gastric disorders, and RIFAXIGEM-550, for bacterial-induced GIT infections—have been the top gastroenterologists’ choice.

FAQ